日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1

通过药理学激活线粒体蛋白酶 OMA1 来靶向治疗侵袭性 B 细胞淋巴瘤

Adrian Schwarzer #, Matheus Oliveira #, Marc-Jens Kleppa, Scott D Slattery, Andy Anantha, Alan Cooper, Mark Hannink, Axel Schambach, Anneke Dörrie, Alexey Kotlyarov, Matthias Gaestel, Todd Hembrough, Jedd Levine, Michael Luther, Michael Stocum, Linsey Stiles, David M Weinstock, Marc Liesa #, Matthew

Overcoming hypoxia-induced functional suppression of NK cells

克服缺氧引起的 NK 细胞功能抑制

Kristen Solocinski, Michelle R Padget, Kellsye P Fabian, Benjamin Wolfson, Fabiola Cecchi, Todd Hembrough, Stephen C Benz, Shahrooz Rabizadeh, Patrick Soon-Shiong, Jeffrey Schlom, James W Hodge

High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies

未分化多形性肉瘤的高通量分析确定了两个主要亚组,它们具有不同的免疫特征、临床结果和对靶向治疗的敏感性

Maud Toulmonde, Carlo Lucchesi, Stéphanie Verbeke, Amandine Crombe, Julien Adam, Damien Geneste, Vanessa Chaire, Audrey Laroche-Clary, Raul Perret, François Bertucci, Frederic Bertolo, Laurence Bianchini, Bérengère Dadone-Montaudie, Todd Hembrough, Steve Sweet, Yeoun Jin Kim, Fabiola Cecchi, Françoi

Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition

通过联合 MEK 和 SHP2 抑制靶向野生型 KRAS 扩增的胃食管癌

Gabrielle S Wong, Jin Zhou, Jie Bin Liu, Zhong Wu, Xinsen Xu, Tianxia Li, David Xu, Steven E Schumacher, Jens Puschhof, James McFarland, Charles Zou, Austin Dulak, Les Henderson, Peng Xu, Emily O'Day, Rachel Rendak, Wei-Li Liao, Fabiola Cecchi, Todd Hembrough, Sarit Schwartz, Christopher Szeto, Anil

Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma

针对特定人群的靶向治疗:EGFR扩增的胃食管腺癌的抗EGFR治疗

Steven B Maron, Lindsay Alpert, Heewon A Kwak, Samantha Lomnicki, Leah Chase, David Xu, Emily O'Day, Rebecca J Nagy, Richard B Lanman, Fabiola Cecchi, Todd Hembrough, Alexa Schrock, John Hart, Shu-Yuan Xiao, Namrata Setia, Daniel V T Catenacci

An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer

抑制 BRAFV600E 突变癌症耐药性演变的方法

Yaohua Xue, Luciano Martelotto, Timour Baslan, Alberto Vides, Martha Solomon, Trang Thi Mai, Neelam Chaudhary, Greg J Riely, Bob T Li, Kerry Scott, Fabiola Cechhi, Ulrika Stierner, Kalyani Chadalavada, Elisa de Stanchina, Sarit Schwartz, Todd Hembrough, Gouri Nanjangud, Michael F Berger, Jonas Nilss

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

具有 3 类 BRAF 突变的肿瘤对抑制激活的 RAS 很敏感

Zhan Yao, Rona Yaeger, Vanessa S Rodrik-Outmezguine, Anthony Tao, Neilawattie M Torres, Matthew T Chang, Matthias Drosten, Huiyong Zhao, Fabiola Cecchi, Todd Hembrough, Judith Michels, Hervé Baumert, Linde Miles, Naomi M Campbell, Elisa de Stanchina, David B Solit, Mariano Barbacid, Barry S Taylor, 

Proof of the quantitative potential of immunofluorescence by mass spectrometry

通过质谱法证明免疫荧光的定量潜力

Maria I Toki, Fabiola Cecchi, Todd Hembrough, Konstantinos N Syrigos, David L Rimm

Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer

MET 抑制和拓扑异构酶 I 抑制联合应用可阻断小细胞肺癌细胞生长

Cleo E Rolle, Rajani Kanteti, Mosmi Surati, Suvobroto Nandi, Immanuel Dhanasingh, Soheil Yala, Maria Tretiakova, Qudsia Arif, Todd Hembrough, Toni M Brand, Deric L Wheeler, Aliya N Husain, Everett E Vokes, Ajit Bharti, Ravi Salgia

Comparative evaluation of strategies for quantifying signaling pathway proteins in Ewing sarcoma

尤文氏肉瘤信号通路蛋白量化策略的比较评估

Mark A Applebaum, Dafydd G Thomas, Todd Hembrough, Jon Burrows, Andrew E Horvai, Elizabeth R Lawlor, Steven G DuBois